Combined lapatinib and paclitaxel in HER2-positive breast cancer

    loading  Checking for direct PDF access through Ovid


A randomized phase III trial evaluated the effect of adding lapatinib to paclitaxel as first-line therapy for patients with metastatic breast cancer whose tumors were negative or untested for human epidermal growth factor receptor 2 (HER2) overexpression. Progression-free survival was prolonged significantly in patients with HER2-overexpressing tumors, which indicates that lapatinib exerts its main effects via the HER2 pathway.

Related Topics

    loading  Loading Related Articles